2nd Annual Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics

This premier B2B event provides the appropriate platform to engage and discuss ideas with your peers, while facilitating a professional atmosphere and environment for good company representation and development.

The summit will shed light on current challenges, best practices and the inside view of the future of ADCs.

We will discuss key findings, including critical insights, as well as recommendations for driving efficient strategies in the ADCs landscape.

Key Practical Learning Points of the Summit:

  • 360° view of Antibody Drug Conjugates (ADCs) from key industry players to leverage your business and scientific practice adoption
  • Emerging discoveries, cutting-edge knowledge, tools, methods, and technologies to design safe and efficient next-generation ADCs
  • Strategies to improve target selection, increase cytotoxic potency, explore developments of novel linker chemistry, applied to next-generation payloads, discover emerging conjugation methods, accelerate preclinical development, and successfully translate into the clinic
  • Approaches to improve the ADC therapeutic risk-benefit ratio, to create new paradigm for novel anti-cancer chemotherapy, to expand the application of ADCs beyond oncology and haematology

Who Should Attend:

Chief Executives, Vice Presidents, Directors, Department Heads, Leaders, Managers, Clinical Development Experts and Scientists specialising in:

  • Antibody & Biologics Discovery /Development
  • Manufacturing/CMC
  • Protein Engineering
  • Molecular Biology
  • Medicinal Chemistry
  • Antibody-drug conjugates (ADCs)
  • Bioconjugates
  • Immunoconjugates
  • Monoclonal antibodies (mAbs)
  • Maytansine
  • Tubulysins
  • Duocarmycin
  • PBD-dimers
  • α-amanitin
  • Topoisomerase inhibitors
  • Marine-based cytotoxins
  • Small-molecule drug conjugates
  • Peptide-drug conjugates
  • Nanoparticles/Nanobodies
  • Diabodies/Minibodies
  • PKPD
  • ADME
  • Toxicology
  • Analytical & Formulation
  • Bioanalysis
  • Cancer
  • Oncology
  • Hematology
  • Antibody-based therapeutics
  • Biotherapeutics
  • Immunotherapeutics
  • Chemotherapeutics
Media partners